Results 41 to 50 of about 2,249 (191)
Frontiers in Medicine, 2023 BackgroundAtopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging.
Bader Bashrahil +9 more
doaj +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]
, 2016 Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei +3 more
core +1 more source
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets. [PDF]
Aging CellImmunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Liu C, Yang M, Xiao F, Zeng J.
europepmc +2 more sources
Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine [PDF]
, 2019 Background: The development of therapeutic vaccines requires thorough knowledge of potential hazards associated with long-term inactivation of self-proteins.
Foerster, John, Molęda, Aleksandra
core +2 more sources
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Frontiers in Immunology, 2022 BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang +11 more
doaj +1 more source
Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. [PDF]
, 2013 Nanocarriers can deliver a wide variety of drugs, target them to sites of interest, and protect them from degradation and inactivation by the body. They have the capacity to improve drug action and decrease undesirable systemic effects.
Bratt, Jennifer M +6 more
core +2 more sources
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
Clinical, Cosmetic and Investigational Dermatology, 2022 Angelina Labib, Teresa Ju, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Email gyosipovitch@med.miami.
Labib A, Ju T, Yosipovitch G
doaj
Genetic basis for personalized medicine in asthma [PDF]
, 2012 There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic ...
Asano +76 more
core +2 more sources